Poster Session B

Poster Session B
Monday, October 17
5:00 p.m.-7:00 p.m.

In alphabetical order, not board assignment order

• A clinical tissue proteomics approach for differential molecular profiling of breast tumor subtypes and individualized care. Sumana Mukherjee1, DaRue A. Prieto2, Josip Blonder2, Donald J. Johann, Jr.1. 1National Cancer Institute, Bethesda, MD, 2NCI-Frederick, Frederick, MD.
• A rank-based statistical test for measuring synergistic effects and its application to Chip-Seq data. Yuichi Shiraishi, Yoshiaki Tanaka, Masao Nagasaki, Satoru Miyano. Human The University of Tokyo, Tokyo, Japan.
• Acetylation-dependent transcriptional regulatory function of human AP-endonuclease (APE1/Ref-1) in lung cancer cell proliferation. Shiladitya Sengupta, Kishor K. Bhakat, Mala Sinha, Bruce A. Luxon, Sankar Mitra. University of Texas Medical Branch, Galveston, TX.
• Clonal analysis and clinical validation of AR signaling in triple-negative breast cancer. Michael T. Barrett1, Travis Henry2, Barbara Pockaj2, Elizabeth Lenkiewicz1, Tara Holley1, Lisa Evers1, Heather E. Cunliffe1, Galen Hostetter1, Ann E. McCullough2, Rafael Fonseca2, Lee McGhan2. 1Translational Genomics Research Institute, Phoenix, AZ, 2Mayo Clinic, Scottsdale, AZ.
• Elucidating the role of E2F2 transcription factor in mediating human breast cancer metastasis. Inez Yuwanita, Eran Andrechek. Michigan State University, East Lansing, MI.
• Epigenetics and cancer: Deregulating key cellular processes and implications in genome expression in breast cancer. Joaquina Martínez-Galán1, Blanca Torres-Torres2, Julia Ruiz Vozmediano1, Jesús López-Peñalver2, Sandra Ríos-Arrabal3, M.I. Núñez-Torres3, J. Ramón Delgado-Pérez1. 1Hospital Universitario Virgen de las Nieves, Granada, Spain, 2Centro de Investigaciones Biomédicas, Granada, Spain, 3Departamento de Radiología y Física Medicina, Granada, Spain.
• Exon-level and gene-level transcriptome profiling for prognostic stratification of stage II and III colorectal cancer. Anita Sveen1, Trude H. Ågesen1, Arild Nesbakken2, Torleiv O. Rognum3, Knut Liestøl4, Rolf I. Skotheim1, Ragnhild A. Lothe1. 1The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway, 2Aker University Hospital, Oslo University Hospital, Oslo, Norway, 3Institute of Forensic Medicine, University of Oslo, Oslo, Norway, 4University of Oslo, Oslo, Norway.
• Family history and BRCA1/2-mutation carriership: Driving forces in choice of breast cancer treatment. Ellen G. Engelhardt1, Mieke G. Kriege2, Matti A. Rookus1, Marjanka K. Schmidt1, Maartje J. Hooning2, Caroline Seynaeve2, Christi J. van Asperen3, Peter Devilee3, Margreet G.E.M. Ausems4. HEBON Collaborators1, Lonneke V. van de Poll-Franse5, Senno Verhoef1. 1Netherlands Cancer Institute, Amsterdam, The Netherlands, 2Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands, 3Leiden University Medical Center, Leiden, The Netherlands, 4University Medical Center Utrecht, Utrecht, The Netherlands, 5Comprehensive Cancer Center South, Eindhoven, The Netherlands.
• From tumors to the laboratory and back again: Genomic analysis of ovarian cancer metastasis reveals a predictive gene signature and therapeutic targets. Alexander S. Brodsky1, Hsin-Ta Wu1, Souriya Vang1, Benjamin J. Raphael1, Laurent Brard2. 1Brown University, Providence, RI, 2Southern Illinois University School of Medicine, Springfield, IL.
• Functional characterization of WAC, a candidate tumor suppressor gene identified by transposon-based genetic screens for intestinal tumors in mice. Caitlin B. Conboy1, Robert T. Cormier2, Tim K. Starr1, David A. Largaespada1, Julia M. Hatler1, Patricia M. Scott2, Aaron L. Sarver1, Kevin A. Silverstein1, Somasekar Seshagiri3, Matthew T. Adams1, Jenna Lillemoe1, Casey R. Dorr1. 1University of Minnesota, Minneapolis, MN, 2University of Minnesota, Duluth, MN, 3Genentech, Inc., South San Francisco, CA.
• Genome-wide analysis of androgen receptor as a transcriptional repressor. Jonathan Zhao, Runkle Christine, Jianjun Yu, Longtao Wu, Jindan Yu. Northwestern University, Chicago, IL.
• Genomic copy number alterations at 1q32.1 and 16q21 stratify patients with high risk for relapse in localized Ewing family of tumors. Fernanda R R Ayala1, Isabela W. Cunha1, Maisa Yoshimoto2, Maria Zielenska3, Fernando A. Soares1, Jeremy A. Squire2. 1A C Camargo Hospital, Sao Paulo, Brazil, 2Queen's University, Kingston, ON, Canada, 3Sick Children Hospital, Toronto, ON, Canada.
• Identification and functional characterization of genomic regions and genes in osteosarcoma metastasis. Yang Washington Shao, Sam Molyneux, Marco Di Grappa, Rama Khokha. Ontario Cancer Institute, Toronto, ON, Canada.
• Identification of predictive biomarkers and development of patient stratification assay for co-targeting mTOR and AKT. Theresa Zhang, Razvan Cristescu, Michael Nebozhyn, Heather Hirsch, Hongyue Dai, Eric Rubin, Gary Gilliland, Jonathan Cheng, Andrey Loboda, Brian Haines, Sriram Sathyanarayanan, Matthew Marton, Igor Feldman, Mary Flynn, Mark Watson. Merck, Boston, MA.
• Identification of ywhae (14-3-3 ε) as an apc interactor that regulates embryonic development and viability. Jennifer L. Yen1, Rodrigo Young2, Nikki H. March3, Doug Winton3, David Adams1, Andy Futreal1, Derek Stemple1. 1Wellcome Trust Sanger Institute, Hinxton, United Kingdom, 2University College London, London, United Kingdom, 3Cancer Research Institute, Cambridge, United Kingdom.
• Identifying molecular markers associated with chemoresistance in ovarian cancer stem cells. Sheetal Dyall1, Kate Lawrenson2, Simon Gayther2. 1University College London, London, England, 2University of Southern California, Los Angeles, CA.
• Innate immunity-associated genetic variants as predictors of prostate cancer risk in men of African descent. K. Sean Kimbro1, Dominique Jones2, Camille Ragin3, Maria Jackson4, Seian Morrison4, Rafael Flores-Obando5, LaCreis R. Kidd2. 1North Carolina Central University, JLC-Biomedical Biotechnology Research Institute, Durham, NC, 2University of Louisville, Louisville, KY, 3Fox Chase Cancer Center, Philadelphia, PA, 4University of West Indies, Kingston, Jamaica, 5Down State University of New York, Downstate Medical Center, Brooklyn, NY.
• Integrated analysis of patient-level genetic aberrations in human cancer. Chris Gates, Matt Anstett, Supra Gajjala, Peter Wyngaard, Daniel Rhodes. Compendia Bioscience, Ann Arbor, MI.
• Loss of DLC1 is an independent prognostic factor in patients with oral squamous cell carcinoma. Satyendra Chandra Tripathi1, Ranju Ralhan2, K.W. Michael Siu2, Jatinder Kaur1, Ajay Matta2, Xin Gao2, Shyam Singh Chauhan1, Alok Thakar1, Nootan Kumar Shukla1, Ritu Duggal1, Mehar Chand Sharma1. 1All India Institute of Medical Sciences, New Delhi, Delhi, India, 2York University, Toronto, ON, Canada.
• Low frequency of early tumor driving mutations in MYCN-amplified neuroblastoma. Jan J. Molenaar, Jan Koster, Danny Zwijnenburg, Marli Ebus, Ida Ploeg vd, Peter Sluis van, Huib N. Caron, Rogier Versteeg. University of Amsterdam, Amsterdam, The Netherlands.
• Massively parallel sequencing of formalin-fixed paraffin-embedded material for copy number analysis in a multiplexed setting. Daoud Sie, Ilari Scheinin, Paul P. Eijk, Danielle Israeli, Gerrit A. Meijer, Bauke Ylstra. VUmc University Medical Center, Amsterdam, The Netherlands.
• NetworkProfiler and its applications in cancer research. Teppei Shimamura, Seiya Imoto, Atsushi Niida, Masao Nagasaki, Rui Yamaguchi, Satoru Miyano. University of Tokyo, Tokyo, Japan.
• Next-generation diagnostics: Expanding clinical actionability of the cancer genome. Alex Parker1, Garrett Frampton1, Amy Donahue1, Sohail Balasubramanian1, John Curran1, Phil Stephens1, Jeffrey Ross2, Gary Palmer1, Maureen Cronin1, Mirna Jarosz1, Frank Juhn1, Kristina Brennan1, Zachary Zwirko1, Sean Downing1, Roman Yelensky1, Doron Lipson1, Geoff Otto1. 1Foundation Medicine, Inc, Cambridge, MA, 2Albany Medical College, Albany, NY.
• Next-generation sequencing based assay for detecting somatic mutations in clinically actionable cancer genes. Shashikant Kulkarni, Mark Watson, John D. Pfeifer, David Spencer, Eric Duncavage, Rakesh Nagarajan, Hussam Al Kateb, Catherine Cottrell, Christina Lockwood, Jacqueline Payton. Washington University School of Medicine, St. Louis, MO.
• Nodular lymphocyte predominant Hodgkin lymphoma: Evaluation of familial risk and genome-wide haplotype comparison of novel familial cases. Silva Saarinen1, Sirkku Karinen1, Rainer Lehtonen1, Mervi Aavikko1, Pia Vahteristo1, Sampsa Hautaniemi1, Eero Pukkala2, Lauri A. Aaltonen1. 1University of Helsinki, Helsinki, Finland, 2The Finnish Cancer Registry, Helsinki, Finland.
• Personalized oncology through integrative high-throughput sequencing: A pilot study. Sameek Roychowdhury1, Michael J. Quist1, Terrence Barrette1, Javed Siddiqui1, Lakshmi P. Kunju1, Nora Navone2, John C. Araujo2, Patricia Troncoso2, Christopher J. Logothetis2, Jeffrey Innis1, David C. Smith1, Matthew K. Iyer1, Christopher Lao1, Scott Kim1, J Scott Roberts1, Stephen B. Gruber1, Kenneth J. Pienta1, Moshe Talpaz1, Arul M. Chinnaiyan1, Dan R. Robinson1, Robert J. Lonigro1, Yi-mi Wu1, Xuhong Cao1, Shanker Kalyana-Sundaram1, Lee Sam1, Oscar Alejandro Balbin1. 1University of Michigan, Ann Arbor, MI, 2University of Texas MD Anderson Cancer Center, Houston, TX.
• Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer: SU2C-001. Michael T. Barrett1, Richard Posner1, Ramesh Ramanathan1, Daniel Von Hoff1, Elizabeth Lenkiewicz1, Lisa Evers1, Tara Holley1, Anirban Maitra2, Rajesh Kumar2, Manuel Hidalgo2, William Hlavacek1, Edward Stites1. 1Translational Genomics Research Institute, Phoenix, AZ, 2Johns Hopkins University, Baltimore, MD.
• RetroSeq: A tool to discover somatic insertion of retrotransposons. Elena Helman1, Mike Lawrence2, Chip Stewart2, Gad Getz2, Matthew Meyerson3. 1Harvard-MIT Health Sciences & Technology, Cambridge, MA, 2Broad Institute, Cambridge, MA, 3Dana-Farber Cancer Institute, Boston, MA.
• Robust gene expression changes as markers for early lapatinib response in a panel of breast cancer cell lines. Fiona O'Neill, Stephen Madden, Sinead Aherne, Martin Clynes, John Crown, Padraig Doolan, Robert O'Connor. Dublin City University, Dublin, Ireland.
• Screening for CHEK2*1100delC heterozygosity and homozygosity in familial breast cancer cases. Marjanka K. Schmidt1, Muriel A. Adank2, Richard van Hien1, Hanne Meijers-Heijboer2, Senno Verhoef1, Laura J. Van 't Veer1, Annegien Broeks1, Frans BL Hogervorst1, Quinten Waisfisz2. 1Netherlands Cancer Institute, Amsterdam, The Netherlands, 2VU Medical Center, Amsterdam, The Netherlands.
• Selection of somatic mtDNA mutations in cancer development. Estella Chen-Quin, Mark Fowler, Ying Xie. Kennesaw State University, Kennesaw, GA.
• Study the risk and prognosis of esophageal cancer by a whole-genomic approach. Ming-Tsang Wu. Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
• The adaptive immune system does not strongly suppress spontaneous tumors in a Sleeping Beauty model of cancer. Laura M. Rogers, Alicia K. Olivier, David K. Meyerholz, Adam J. Dupuy. University of Iowa, Iowa City, IA.
• The overexpression of glutathione peroxidase (GPX) in response to doxorubicin exposure of canine mammary tumor: In vitro study. Camila Leonel1, Bruna Victorasso Jardim1, Juliana Ramos Lopes1, Gabriela Bottaro Gelaleti1, Glaucia Maria de Mendonca Fernandes2, Debora Aparecida Pires de Campos Zuccari1. 1Universidade Estadual Paulista “Júlio de Mesquita Filho” – UNESP/IBILCE, São José Do Rio Preto, Brazil, 2Laboratory of Cancer Molecular Investigation - Faculty of Medicine, São José do Rio Preto, São Paul, São José Do Rio Preto, Brazil.
• Viability screens in leukemic and breast cancer cells with pooled lentiviral shRNA libraries identify potential therapeutic targets and synergistic lethal interactions. Donato Tedesco1, Kyle Bonneau1, Mikhail Makhanov1, Debbie Deng1, Gus Frangou2, Alex Chenchik1. 1Cellecta, Inc., Mountain View, CA, 2Fred Hutchinson Cancer Research Center, Seattle, WA.
• W-EEM: A web service for module discovery form omics data. Atsushi Niida, Teppei Shimamura, Georg Tremmel, Seiya Imoto, Masao Nagasaki, Satoru Miyano. University of Tokyo, Tokyo, Japan.
• Whole transcriptome analysis of African American and Caucasian triple-negative breast cancer samples using RNA-Seq. Shukmei Wong1, Jessica Aldrich1, Bodour Salhia1, Asim Siddiqui2, Linh Hoang2, Jeffrey M. Trent1, Jeffrey Kiefer1, Spyro Mousses1, Daniel Von Hoff1, David W. Craig1, John D. Carpten1, Joyce A. O’Shaughnessy3, Shripad Sinari1, Tracy M. Moses1, Tyler Izatt1, Alexis Christoforides1, Jennifer Dinh1, Joanne Blum3, Ahmet Kurdoglu1. 1Translational Genomics Research Institute, Phoenix, AZ, 2Life Technologues, Carlsbad, CA, 3US Oncology, Baylor Sammons Cancer Center, Dallas, TX.
• Whole-genome sequencing of Nigerian Breast Cancer Cohort. Toshio F. Yoshimatsu, Yonglan Zheng, Dezheng Huo, Thomas Stricker, Kevin P. White, Olufunmilayo I. Olopade. The University of Chicago, Chicago, IL.